References
- Phillips A, Demarest K, Hahn D W., Wong F, McGuire J L. Progestational and androgenic receptor binding affinities and in vivo activity of norgestimate and other progestins. Contraception 1990; 41: 399–410
- McGuire J L., Phillips A, Hahn D W., Tolman E L., Flor S, Kafrissen M E. Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites. Am J Obstet Gynecol 1990; 163: 2137–31
- Phillips A, Hahn D W., McGuire J L. Relative binding affinity of norgestimate and other progestins for human sex hormone binding globulin. Steroids 1990; 55: 373–75
- Chapdelaine A, Desmarais J L., Derman R J. Clinical evidence of the minimal androgenic activity of norgestimate. Int J Fertil 1989; 34: 347–52
- Corson S L. Efficacy and clinical profile of a new oral contraceptive containing norgestimate: US clinical trials. Acta Obstet Gynecol Scand Suppl 1990; 69: 25–31
- Becker H. Supportive European data on a new oral contraceptive containing norgestimate. Acta Obstet Gynecol Scand Suppl 1990; 69: 33–9
- Grunwald K, Rabe T, Runnebaum B. Clinical tolerance of a low-dose norgestimate-containing combination oral contraceptive (Cilest) in a West German multicenter study (Heidelberg Multicenter Oral Contraceptive Study). Aktuelle Aspekte der Hormonalen Kontraception, P J. Keller. Karger, Basel 1991; 67–78